Sten Westerberg joins BioInvent

pharmafile | April 26, 2011 | Appointment | Research and Development appointment, research and development, sales and marketing 

Swedish pharma company BioInvent International has appointed Sten Westerberg to the newly-created position of vice president investor relations.

Sten is currently sector head at Öhman Fondkommission, Healthcare Equity Research and previously worked as a pharmaceutical analyst at Swedbank Markets and a stock market journalist at the Veckans Affärer.

“We are very pleased to have recruited Sten who has a long experience in capital markets with focus on the pharmaceutical industry,” said BioInvent’s chief executive Svein Mathisen.

Advertisement

“BioInvent is at an exciting stage with several drug candidates advancing in the clinical trials. I look forward to working with Sten to further increase the awareness of BioInvent.”

BioInvent focuses on developing antibody drugs and has four clinical development projects across thrombosis, cancer and atherosclerosis. It has also partnered with a number of companies, including Genentech, Human Genome Sciences, Roche and ThromboGenics.

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content